PRIMARY MYELOFIBROSIS (PMF)
Clinical trials for PRIMARY MYELOFIBROSIS (PMF) explained in plain language.
Never miss a new study
Get alerted when new PRIMARY MYELOFIBROSIS (PMF) trials appear
Sign up with your email to follow new studies for PRIMARY MYELOFIBROSIS (PMF), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo pill aims to shrink spleens and ease symptoms in bone marrow cancer
Disease control Recruiting nowThis phase 3 trial tests whether adding pelabresib to the standard drug ruxolitinib works better than ruxolitinib alone for people with myelofibrosis, a type of bone marrow cancer. About 460 adults who have not taken JAK inhibitors before will receive either the combination or a …
Matched conditions: PRIMARY MYELOFIBROSIS (PMF)
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New pill combo aims to tame bone marrow cancer
Disease control Recruiting nowThis early-phase study tests whether adding a new drug called pelabresib to the standard treatment ruxolitinib is safe and helpful for Japanese adults with myelofibrosis, a type of bone marrow cancer. Only 6 people will take part, and the main goal is to check for side effects an…
Matched conditions: PRIMARY MYELOFIBROSIS (PMF)
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for rare blood cancers: first human trial of PRT12396 begins
Disease control Recruiting nowThis early-stage study tests a new drug, PRT12396, in about 100 people with polycythemia vera or myelofibrosis—rare blood cancers. The main goals are to find a safe dose and check for side effects. Researchers will also look for signs that the drug controls the disease, but this …
Matched conditions: PRIMARY MYELOFIBROSIS (PMF)
Phase: PHASE1 • Sponsor: Prelude Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Desperate patients get early access to promising drug
Disease control AVAILABLEThis program provides early access to the drug ruxolitinib for people with serious or life-threatening conditions like certain blood cancers, severe COVID-19, or graft-versus-host disease. It is for patients who have no other treatment options and cannot join a clinical trial. Th…
Matched conditions: PRIMARY MYELOFIBROSIS (PMF)
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Scientists hunt for immune cells that could lead to new MPN therapies
Knowledge-focused Recruiting nowThis study looks at how the immune system reacts to myeloproliferative neoplasms (MPN), a group of blood cancers. Researchers will collect blood and bone marrow samples from 150 adults with or without MPN to find special immune cells (T cells) that recognize and attack MPN cells.…
Matched conditions: PRIMARY MYELOFIBROSIS (PMF)
Sponsor: Université Catholique de Louvain • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Massive new study aims to unlock secrets of rare blood cancers
Knowledge-focused Recruiting nowThis long-term observational study is enrolling 5,000 adults with myeloproliferative neoplasms (MPNs)—rare blood cancers like polycythemia vera and myelofibrosis. Researchers will collect health records, patient surveys, and insurance data over at least five years to track sympto…
Matched conditions: PRIMARY MYELOFIBROSIS (PMF)
Sponsor: MPN Research Foundation • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC